ProfitScout
3週前
$COSM News: Cosmos Health CEO Issues Letter to Shareholders: Building an Innovative AI-Driven Global Healthcare Platform — Record Growth with U.S. Expansion Underway
https://www.globenewswire.com/news-release/2026/06/10/3309738/0/en/cosmos-health-ceo-issues-letter-to-shareholders-building-an-innovative-ai-driven-global-healthcare-platform-record-growth-with-u-s-expansion-underway.html
Key Highlights
Record revenue, continued momentum: all-time high $65.3M in FY2025; strongest-ever Q1 2026, carrying into Q2.
Record operational momentum: CosmoFarm wholesale distribution and GMP-certified Cana contract manufacturing both delivering record volumes.
Guidance signaling potential financial transformation: targeting over $200M revenue, $44.2M Adjusted EBITDA, and $92.3M stockholders' equity by 2029.
Global brand momentum: Sky Premium Life, 18 Series, and C-Scrub scaling from Europe and the Middle East to the U.S., with C-Scrub now extending into the global animal health industry.
Advancing R&D pipeline: spanning oncology, neurology, and inflammation, supported by our AI-driven Cloudscreen platform and nanotechnology investments.
CCX0722 — Obesity: proprietary weight-management product in final development phase, targeting a global market projected to reach ~$299Bn by 2030.
Landmark financing: pursuing a financing program of up to €25M with the European Investment Bank.
U.S. market entry active and generating revenue: local manufacturing, with projected annualized revenue, including Noor18, exceeding $20M at ~75% gross margins within 12–18 months.
Strength through diversification: a vertically integrated platform spanning distribution, contract manufacturing, proprietary brands, and R&D, with ~$20M in non-core assets identified to unlock value.
CEO commitment, aligned with shareholders: continued insider share purchases, reflecting management's conviction in the long-term value being created.
Golden Cross
4週前
$COSM Could Be 2026’s Most Volcanic Breakout!
Cosmos Health (NASDAQ: COSM) on Track for Explosive Growth: $200M Revenue Target by 2029
Cosmos Health Inc. has unveiled highly bullish 2026–2029 guidance, positioning the company as a fast-growing, high-margin healthcare platform with strong cash generation potential.
Revenue is projected to surge 207% at a 32% CAGR, climbing from $65.3 million in 2025 to $200.6 million by 2029. Gross profit is expected to explode 801% to $71.2 million, driving gross margins from 12.1% to 35.5% — a remarkable 2,340 basis point expansion fueled by a strategic shift to proprietary nutraceuticals, contract manufacturing, and higher-margin products.
Key milestones ahead:
Net income turns positive in 2027, reaching $31.0 million by 2029
Adjusted EBITDA climbs to $44.2 million (22.1% margin)
Operating cash flow turns positive in 2027 and doubles to $24.0 million by 2029
Cash balance surges 18x to $62.9 million, with all convertible notes repaid and stockholders’ equity rising 402% to $92.3 million
The company is building momentum through seven key growth pillars: the expanding 18 Series nutraceuticals (including new Fort18™ men’s wellness product), Sky Premium Life® global rollout, Cana Laboratories manufacturing scale-up, AI-driven efficiencies, R&D pipeline acceleration (with potential €25M EIB financing), U.S. market entry, and selective M&A.
Recent highlights reinforce the positive trajectory: record Q1 2026 revenue of $17.9 million (+31% YoY), significant debt reduction, warrant overhang cut by 38% with zero dilution, and continued share purchases by CEO Greg Siokas.
“ We are at a critical inflection point,” said CEO Greg Siokas. “We are transforming both the scale and quality of earnings while building a self-funding, high-margin healthcare platform.”
With improving fundamentals, margin expansion, and a clear path to profitability and strong cash flow, Cosmos Health is well-positioned to deliver substantial long-term shareholder value. The $200 million revenue platform is coming into focus — and the opportunity ahead looks compelling.
Golden Cross
4週前
$COSM 🗞️ Cosmos Health Achieves Pan-European Distribution for Sky Premium Life Across All 27 EU Member States Through Leading E-Commerce Platform Skroutz
🔗 https://markets.financialcontent.com/stocks/article/gnwcq-2026-6-4-cosmos-health-achieves-pan-european-distribution-for-sky-premium-life-across-all-27-eu-member-states-through-leading-e-commerce-platform-skroutz
CHICAGO, June 04, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ: COSM), a diversified, vertically integrated global healthcare group, today announced that its proprietary brand, Sky Premium Life, is now available for shipment across all 27 European Union Member States through Skroutz, significantly expanding the brand’s international reach.
A total of 96 Sky Premium Life products are now accessible to consumers across all 27 European Union Member States through Skroutz, with shipments reaching key markets across Western Europe, Northern Europe, and Central and Eastern Europe. The countries covered include Austria, Belgium, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, and Sweden.
Skroutz is one of the leading e-commerce platforms in Southeast Europe, connecting millions of consumers with a wide network of merchants and brands. Its cross-border capabilities enable efficient distribution and localized access to products across multiple European markets, making it a strategic channel for international expansion.
The Company believes that this expanded distribution footprint further strengthens the global positioning of the Sky Premium Life brand, enabling broader market penetration and increased accessibility to its portfolio of premium nutraceutical and wellness products.
Greg Siokas, CEO of Cosmos Health, stated: "The expansion of Sky Premium Life across all 27 EU Member States through Skroutz represents a key milestone in our international growth strategy. By leveraging Skroutz’s cross-border infrastructure, we are able to efficiently scale distribution and reach consumers across Europe. This initiative further enhances our brand visibility and supports our continued focus on driving revenue growth and expanding our global presence.”
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
resx18
4週前
CHICAGO, June 02, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today provides an update on its balance sheet and notes no known business reason for the recent decline in its share price.
While many of these developments have been reported individually, the Company believes it is important for investors to consider them collectively, as they reflect a business undergoing a fundamental balance sheet transformation.
Balance Sheet Continues to Strengthen
Cosmos Health's balance sheet is trending positively across multiple key metrics, as reported in the Company's Q1 2026 results:
Total liabilities decreased by $4.5 million, or 9.6%, quarter-over-quarter, driven by a substantial reduction in convertible note and credit facility balances
Stockholders' equity increased by $1.4 million, or 7.6%, quarter-over-quarter
Liabilities-to-assets ratio improved by 370 basis points to 68.2% from 71.9% at year-end 2025
Liquid assets of $4.3 million comprising cash of $2.2 million and digital assets and marketable securities of $2.1 million
Beyond the quarterly metrics, Cosmos Health's balance sheet is underpinned by a diversified asset base spanning GMP-certified manufacturing facilities, a robotic logistics warehouse, pharmaceutical distribution infrastructure, proprietary intellectual property, digital assets, and a growing U.S. commercial platform.
European Investment Bank — A Milestone for Cosmos Health's R&D
Cosmos Health's R&D division is in discussions with the European Investment Bank (EIB) for financing of up to €25 million under the EIB's Venture Debt Program, reflecting up to 50% of its broader €50 million R&D initiative. The EIB is the lending arm of the European Union and one of the world's leading multilateral financing institutions. If successfully concluded, this financing would represent a significant milestone for the Company's R&D platform, which is anchored by the proprietary AI-driven Cloudscreen drug repurposing technology and spans oncology, autoimmune diseases, neurology, and obesity.
Capital Structure Simplified — Zero Dilution
4,874,126 Series B Warrants have expired unexercised, eliminating approximately 38% of total outstanding warrants with no shareholder dilution. This represents a meaningful simplification of the Company's capital structure that directly benefits existing shareholders.
Real Estate Assets — Wholly Owned, Independently Valued at over $15 Million
Cosmos Health holds real estate assets — its CosmoFarm distribution facility and Cana Laboratories manufacturing site — with a combined fair market value of approximately $15 million, wholly owned and independently valued. A large portion of these assets are free of any mortgage or other financial encumbrance, providing the Company with additional financial flexibility. The market value of these assets alone exceed the Company's current market capitalization and represent a meaningful component of the Company's asset base the Company believes is not yet reflected in its share price.
Digital Asset Strategy — A Forward-Looking Treasury Approach
The Company secured a financing facility of up to $300 million to support its digital assets treasury strategy. The Company has commenced investments in digital assets, with the strategy providing balance sheet diversification and a platform to explore blockchain’s practical applications in healthcare, while retaining significant capital for core operations.
Record Momentum and Balance Sheet Transformation
Cosmos Health is growing at its fastest pace in Company history — FY2025 revenue of $65.3 million was an all-time annual record, up 20% year-over-year with gross profit growing 83%, followed by Q1 2026 revenue of $17.9 million, the highest Q1 in Company history, up 31% year-over-year, with momentum continuing into Q2 2026 across all core divisions.
The Company's recently published 2026–2029 guidance projects this trajectory to drive a structural transformation of the balance sheet: revenue growing to $200.6 million by 2029 at a 32% CAGR, gross margins expanding from 12.1% to 35.5%, Adjusted EBITDA reaching $44.2 million, operating cash flow of $24 million, a cash position of $62.9 million, and stockholders' equity growing 402% to $92.3 million — with all convertible debt projected to be fully repaid and cash expected to exceed total debt by 2027.
Greg Siokas, CEO of Cosmos Health, stated: “The fundamentals speak for themselves. Total liabilities are down $4.5 million in a single quarter, while stockholders' equity is up 7.6%. The market value of our real estate assets alone — wholly owned and independently valued at approximately $15 million — exceeds our current market capitalisation. Our R&D division is in discussions with the European Investment Bank for financing of up to €25 million toward a €50 million R&D program. We have eliminated 38% of our warrant overhang with zero dilution to shareholders. And our guidance projects revenue more than tripling to $200.6 million by 2029, with stockholders' equity growing fourfold to $92.3 million and a cash position of $62.9 million. We are aware that our share price has not reflected this progress, and we do not believe that disconnect is justified by our fundamentals. The growth is happening. We look forward to demonstrating that in the quarters ahead.”
Golden Cross
1月前
$COSM Cosmos Health enters this guidance period following its strongest financial performance in Company history — full year 2025 revenue of $65.3 million, up 20% year-over-year, with gross profit increasing 83%, gross margin expanding 418 basis points, and cash rising more than tenfold to $3.5 million. This momentum has carried into 2026 across all core segments, with the Company expecting to surpass $90 million in revenue in 2026, representing approximately 38% year-over-year growth, and continued strong growth anticipated through 2029. By 2029, Cosmos Health projects revenue of $200.6 million, gross profit of $71.2 million, net income of $31.0 million, Adjusted EBITDA of $44.2 million, and cash of $62.9 million, with all convertible debt expected to be fully repaid and stockholders' equity projected to increase 402% to $92.3 million.
resx18
1月前
CHICAGO, June 01, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the extension of its C-Scrub antimicrobial wash brand into the veterinary and animal health sector through the planned launch of a veterinary formulation of C-Scrub Wash 4%, marking the Company’s first entry into the animal health market.
The Company intends to launch the veterinary formulation in the United Kingdom, where C-Scrub is already an established and commercially active human-use brand, with broader international expansion to follow.
The global animal health market was estimated at approximately $68.7 billion in 2025 and is projected to reach $156.0 billion by 2033, growing at a compound annual growth rate of 11.0%, according to Grand View Research.
Brand Extension into Animal Health
C-Scrub Wash 4%, manufactured by the Company’s wholly owned subsidiary Cana Laboratories S.A., is a commercially available human-use antimicrobial skin cleanser.
The Company is now extending the C-Scrub brand into the veterinary space following successful independent testing of C-Scrub Wash 4% according to European veterinary disinfectant standards.
This extension leverages the existing product, manufacturing infrastructure, and brand equity of C-Scrub to address a distinct and rapidly growing segment within animal healthcare.
European Veterinary Standards Testing
C-Scrub Wash 4% successfully demonstrated bactericidal activity according to EN 1656:2019 and yeasticidal activity according to EN 1657:2024 following independent testing conducted by Quality Assurance & Control Systems Ltd. (QACS), an EU-based testing laboratory accredited according to EN ISO/IEC 17025:2017. Testing was conducted in May 2026 under clean conditions (3g/L bovine albumin) at 20°C with a 10-minute contact time.
Under EN 1656:2019, C-Scrub Wash 4% demonstrated bactericidal activity meeting the required ≥5 log reduction criterion against four reference organisms required under EN 1656 testing — Pseudomonas aeruginosa, Staphylococcus aureus, Proteus hauseri, and Enterococcus hirae — at both undiluted (80%) and 50% concentrations.
Under EN 1657:2024, the product demonstrated yeasticidal activity meeting the required ≥4 log reduction criterion against Candida albicans at both undiluted (80%) and 50% concentrations.
Greg Siokas, CEO of Cosmos Health, stated: “The successful testing of C-Scrub Wash 4% under EN 1656 and EN 1657 represents an important milestone as we extend a brand we have already established in the human healthcare market into the fast-growing veterinary sector. This marks Cosmos Health's first entry into animal health, and we believe that combining existing C-Scrub brand awareness, manufacturing capabilities, and distribution infrastructure positions us to pursue meaningful commercial opportunities globally.”
Golden Cross
1月前
$COSM Breaking News-->> Cosmos Health Enters $69 Billion Global Animal Health Industry with Veterinary C-Scrub Wash 4% Following Successful European Standard Testing Under EN 1656 and EN 1657
🔗 https://www.globenewswire.com/news-release/2026/06/01/3304348/0/en/cosmos-health-enters-69-billion-global-animal-health-industry-with-veterinary-c-scrub-wash-4-following-successful-european-standard-testing-under-en-1656-and-en-1657.html
CHICAGO, June 01, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the extension of its C-Scrub antimicrobial wash brand into the veterinary and animal health sector through the planned launch of a veterinary formulation of C-Scrub Wash 4%, marking the Company’s first entry into the animal health market.
The Company intends to launch the veterinary formulation in the United Kingdom, where C-Scrub is already an established and commercially active human-use brand, with broader international expansion to follow.
The global animal health market was estimated at approximately $68.7 billion in 2025 and is projected to reach $156.0 billion by 2033, growing at a compound annual growth rate of 11.0%, according to Grand View Research.
Brand Extension into Animal Health
C-Scrub Wash 4%, manufactured by the Company’s wholly owned subsidiary Cana Laboratories S.A., is a commercially available human-use antimicrobial skin cleanser.
The Company is now extending the C-Scrub brand into the veterinary space following successful independent testing of C-Scrub Wash 4% according to European veterinary disinfectant standards.
This extension leverages the existing product, manufacturing infrastructure, and brand equity of C-Scrub to address a distinct and rapidly growing segment within animal healthcare.
European Veterinary Standards Testing
C-Scrub Wash 4% successfully demonstrated bactericidal activity according to EN 1656:2019 and yeasticidal activity according to EN 1657:2024 following independent testing conducted by Quality Assurance & Control Systems Ltd. (QACS), an EU-based testing laboratory accredited according to EN ISO/IEC 17025:2017. Testing was conducted in May 2026 under clean conditions (3g/L bovine albumin) at 20°C with a 10-minute contact time.
Under EN 1656:2019, C-Scrub Wash 4% demonstrated bactericidal activity meeting the required =5 log reduction criterion against four reference organisms required under EN 1656 testing — Pseudomonas aeruginosa, Staphylococcus aureus, Proteus hauseri, and Enterococcus hirae — at both undiluted (80%) and 50% concentrations.
Under EN 1657:2024, the product demonstrated yeasticidal activity meeting the required =4 log reduction criterion against Candida albicans at both undiluted (80%) and 50% concentrations.
Greg Siokas, CEO of Cosmos Health, stated: “The successful testing of C-Scrub Wash 4% under EN 1656 and EN 1657 represents an important milestone as we extend a brand we have already established in the human healthcare market into the fast-growing veterinary sector. This marks Cosmos Health's first entry into animal health, and we believe that combining existing C-Scrub brand awareness, manufacturing capabilities, and distribution infrastructure positions us to pursue meaningful commercial opportunities globally.”
About C-Scrub Wash 4% for Animal Healthcare
C-Scrub Wash 4% is an antimicrobial wash containing the active substance Chlorhexidine Digluconate 4% w/v — a broad-spectrum antimicrobial agent. Already commercially available for human use, the formulation is now being extended for animal healthcare applications in veterinary environments including breeding, husbandry, veterinary care facilities, transport environments, and related professional settings.
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq: COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
puffadder
5日前
EpicSage
2週前
BigBadWolf
2週前
Trooperstocks
4週前
fliper
4週前
glenn1919
4週前
Monroe1
4週前
メールアドレスで登録
